|
Malignant neoplasm of stomach
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Over expression of amphiregulin promoted malignant progression in gastric cancer.
|
31466817 |
2019 |
|
Malignant neoplasm of stomach
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
|
26884344 |
2017 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
BEFREE |
The results indicated that Trop2+/AREG+ coexpression was higher in GC tissues than in adjacent tissues.
|
28256068 |
2017 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
BEFREE |
Thus, over-expression of AREG could serve as a novel GC biomarker, and active surveillance of its expression could be a novel approach to GC diagnosis and monitoring.
|
27713123 |
2016 |
|
Malignant neoplasm of stomach
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
AREG rs1615111, located in the AREG genomic region, can significantly define different prognostic cohorts in locally advanced GC.
|
25203737 |
2014 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
BEFREE |
The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
|
21482691 |
2011 |
|
Malignant neoplasm of stomach
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Methylation status of the 32 randomly selected and 16 potential tumor-related genes was analyzed in 10 primary gastric cancers, and 42 genes (ABHD9, ADFP, ALDH1A3, ANXA5, AREG, BDNF, BMP7, CAV1, CDH2, CLDN3, CTSL, EEF1A2, F2R, FADS1, FSD1, FST, FYN, GPR54, GREM1, IGFBP3, IGFBP7, IRS2, KISS1, MARK1, MLF1, MSX1, MTSS1, NT5E, PAX6, PLAGL1, PLAU, PPIC, RBP4, RORA, SCRN1, TBX3, TFAP2C, TNFSF9, ULBP2, WIF1, ZNF177 and ZNF559) were methylated in at least one primary gastric cancer.
|
16367923 |
2006 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
CTD_human |
Methylation status of the 32 randomly selected and 16 potential tumor-related genes was analyzed in 10 primary gastric cancers, and 42 genes (ABHD9, ADFP, ALDH1A3, ANXA5, AREG, BDNF, BMP7, CAV1, CDH2, CLDN3, CTSL, EEF1A2, F2R, FADS1, FSD1, FST, FYN, GPR54, GREM1, IGFBP3, IGFBP7, IRS2, KISS1, MARK1, MLF1, MSX1, MTSS1, NT5E, PAX6, PLAGL1, PLAU, PPIC, RBP4, RORA, SCRN1, TBX3, TFAP2C, TNFSF9, ULBP2, WIF1, ZNF177 and ZNF559) were methylated in at least one primary gastric cancer.
|
16367923 |
2006 |
|
Malignant neoplasm of stomach
|
0.360 |
Therapeutic
|
disease |
CTD_human |
The findings reported here demonstrate that SN38 (the active metabolite of CPT-11) induces the tyrosine phosphorylation of EGFR within 5 min, followed by the induction of transcripts and/or proteins of the heparin-binding EGF-like growth factor, amphiregulin, transforming growth factor-alpha, and interlukin-8 (IL-8) in AGS gastric cancer cells.
|
15723263 |
2005 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
CTD_human |
The findings reported here demonstrate that SN38 (the active metabolite of CPT-11) induces the tyrosine phosphorylation of EGFR within 5 min, followed by the induction of transcripts and/or proteins of the heparin-binding EGF-like growth factor, amphiregulin, transforming growth factor-alpha, and interlukin-8 (IL-8) in AGS gastric cancer cells.
|
15723263 |
2005 |
|
Malignant neoplasm of stomach
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
15940630 |
2005 |
|
Malignant neoplasm of stomach
|
0.360 |
Biomarker
|
disease |
CTD_human |
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
15940630 |
2005 |